Join IAG’s Expert Team at EULAR 2023: Novel ideas for drug development. Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma. The Invitation-only network for founders &CEOs of the most successful scaleups. Dr Kubassova is a leading innovator and passionate investor in healthcare. Presenting new data from Ulcerative Colitis trial at DDW 2023.
London, United Kingdom
Founded in 2007
51-100 Employees
Medium-Sized
Working industry
Finance and Insurance
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
3 Locations
Number of products
6 Products
Specialised areas
Artificial Intelligence, Machine Learning, Pharmaceutical, Research, Cloud Infrastructure, Image Recognition, Clinical Trials, Venture Capital, Medical, Biotechnology
IAG, Image Analysis Group offers a wide range of products and services
Product
Age-related Macular Degeneration (AMD) | IAG
Go to product >
Product
LUMBAR DISC DISEASE / SPINE | IAG
Go to product >
Product
MULTIPLE SCLEROSIS | IAG
Go to product >
Product
PSORIATIC ARTHRITIS | IAG
Go to product >
Product
Role of tissue perfusion, muscle strength recovery and pain in rehabilitation after acute muscle strain injury: A randomized controlled trial comparing early and delayed rehabilitation | IAG
Go to product >
Product
OPHTALMOLOGY | IAG
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United Kingdom
Overall risk estimation:
Very low
The ESG Data of countries are based on public sources
Environment
A
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Get insights into the use cases of IAG, Image Analysis Group
Use case
AltruBio and IAG, Image Analysis Group Partner to Deploy AI in Gastrointerology | IAG
AltruBio and IAG teams will be deploying AI to assess patient response in phase 2 IBD study | Privacy Overview
Use case
MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program | IAG
Image Analysis Group to Partner with MIMEDX in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program | Privacy Overview
IAG, Image Analysis Group operates in 3 countries around the world
Get an overview of the locations of IAG, Image Analysis Group
Location
Country
State
City
Headquarter
United Kingdom
England
London
IMAGE ANALYSIS, INC
United States
Pennsylvania
Philadelphia
IAG Image Analysis Private Limited
India
Telangana
Hyderabad
Some frequent questions that have been asked about IAG, Image Analysis Group
Where is IAG, Image Analysis Group located?
The company headquarter of IAG, Image Analysis Group is located in London, England, United Kingdom. IAG, Image Analysis Group has subsidiaries in United States, India
How many employees does IAG, Image Analysis Group approximately have?
As of the latest available information IAG, Image Analysis Group has around 51-100 employees worldwide.
When was IAG, Image Analysis Group founded?
IAG, Image Analysis Group was founded in 2007
In which industries does IAG, Image Analysis Group mainly work?
The company IAG, Image Analysis Group has it's main focus in the industries of Finance and Insurance
What is the current company status of IAG, Image Analysis Group?
Based on the founding year and the amount of employees the company IAG, Image Analysis Group seems to be a Medium-Sized at the current state. Note that over time that status can change
Check out some interesting alternative companies to IAG, Image Analysis Group
Digital Rheumatology Network
Lausanne, Switzerland
251-500 Employees
2019
to build a strong and international community who shares knowledge and experience in upcoming digital solutions in Rheumatology. to connect leading experts from a wide variety of disciplines like Physicians, Pharma and MedTech industry, Health IT companies, Associations, Consultants and Academia as well as Research Centers to discover new innovative practices. to explore the future and understand what´s going to be next! This network aims to provide an overview on pioneering developments of therapies in digital Biomarker, artificial intelligence, applications, machine learning etc. in Rheumatology. Our community enables mutual exchange between a wide range of stakeholders and brings to the foreground innovative solutions meeting tomorrow’s challenges in Rheumatology. Data scientists, software/application developer, computer programmer, IT specialists etc.
13295 - Dermatology Drug Development EU
London, United Kingdom
1-10 Employees
-
As experts gather to address common challenges and share how novel R&D is rapidly re-shaping therapeutic approaches to expedite drugs addressing complex and heterogenous disease, this is your crucial industry touchpoint for gaining the best picture of the future directions of the field. Learn how patient-centric studies are optimising drug delivery and formulation strategies whilst planning ahead for regulatory scrutiny, with Sol-Gel Technologies and Blueberry Therapeutics, to see improved efficacy, adherence and clinical translation success.
AICURA medical GmbH
Berlin, Germany
11-50 Employees
2018
We are on a mission to improve patient outcomes by revolutionizing clinical drug development through a dynamic, secure, and collaborative data ecosystem.. We provide you with an interoperable graph-based data layer and an intuitive user interface that allows you to easily access, query, and visualize all of your data. We are excited to announce that we have been selected to present at the 36th Global Conference of Alzheimer's Disease International (ADI), in Krakow, from April 24-26, 2024. We are thrilled to announce the expansion of our data x AI ecosystem by partnering with a leading research group in the field of neurodegenerative diseases. AICURA is a leading data and AI company with a focus on healthcare and life sciences. With a mission to enhance patient outcomes, AICURA has built a secure and collaborative data and AI ecosystem. AICURA connects various stakeholders, including biotech firms, healthcare providers, medtech companies, clinical researchers, and Contract Research Organizations (CROs), establishing a comprehensive network for data, technology, and knowledge transfer across the healthcare industry. The platform has already been adopted by leading academic institutions for clinical research.
Bioqube Ventures
Brussels, Belgium
1-10 Employees
2015
Bicara Therapeutics is a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response. Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones. Enhanc3D Genomics is a functional genomics company that has developed a proprietary disruptive technology to profile three-dimensional genome folding at high resolution.Understanding DNA organization and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes.Enhanc3D Genomics has a mission to be a first in class high precision navigator of the non-coding regions of the genome hereby unlocking novel disease-related targets. Anavo’s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class. Bioqube Ventures is a specialist life sciences investment firm based in Europe with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. Europe is a proven pool for hidden gems ready to be transformed into international biotechs. With our in-house “factory” model we are able to translate exciting science into trailblazing companies.
e-INS (INS European Chapters)
Hamburg, Germany
11-50 Employees
-
Discover the experts that will be presenting at e-INS 2023.
Atlantic Healthcare
Uttlesford, United Kingdom
11-50 Employees
2006
Working with key opinion leaders on our international Medical Advisory Board, we are currently developing differentiated, first-in-class treatments that leverage alicaforsen, an antisense therapeutic agent with a novel target for validated mechanism of action and the potential to treat multiple inflammatory GI diseases. Our mission is to work collaboratively with healthcare providers and patient groups in pursuit of treatments which improve the quality of life of patients with unmet medical needs. Our vision is to be acknowledged as a leading global specialist pharmaceutical company with a portfolio of therapeutics that meet the needs of patients, healthcare providers and the wider healthcare community, while providing acceptable shareholder returns. Our Board offers a wealth of experience in growing successful pharmaceutical companies, having held leadership roles in large multi-national firms. Our international Medical Advisory Board comprises a group of eminent clinicians who provide expert advice and counsel to inform the development of our pipeline.